Diabetes technology company Tandem Diabetes Care NASDAQ:TNDMmet Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.8% year on year to $254.6 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $1.08 billion at the midpoint. Its GAAP loss of $0.31 per share was in line with analysts’ consensus estimates.
Tandem Diabetes (TNDM) Q2 CY2026 Highlights:
- Revenue: $254.6 million vs analyst estimates of $253.8 million (5.8% year-on-year growth, in line)
- EPS (GAAP): -$0.31 vs analyst estimates of -$0.32 (in line)
- Adjusted EBITDA: $6.42 million vs analyst estimates of $3.52 million (2.5% margin, 82.2% beat)
- The company reconfirmed its revenue guidance for the full year of $1.08 billion at the midpoint
- Operating Margin: -5.4%, up from -21.5% in the same quarter last year
- Free Cash Flow was -$38.67 million compared to -$15.7 million in the same quarter last year
- Market Capitalization: $1.34 billion
Company Overview
With technology that automatically adjusts insulin delivery based on continuous glucose monitoring data, Tandem Diabetes Care NASDAQ:TNDM develops and manufactures automated insulin delivery systems that help people with diabetes manage their blood glucose levels.
Revenue Growth
Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, Tandem Diabetes’s sales grew at a decent 11.5% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.
We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Tandem Diabetes’s annualized revenue growth of 12.8% over the last two years is above its five-year trend, suggesting its demand recently accelerated.
This quarter, Tandem Diabetes grew its revenue by 5.8% year on year, and its $254.6 million of revenue was in line with Wall Street’s estimates.
Looking ahead, sell-side analysts expect revenue to grow 9.3% over the next 12 months, a deceleration versus the last two years. Still, this projection is commendable and suggests the market sees success for its products and services.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. .
Adjusted Operating Margin
Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits.
Tandem Diabetes’s high expenses have contributed to an average adjusted operating margin of negative 8.6% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It’s hard to trust that the business can endure a full cycle.
Analyzing the trend in its profitability, Tandem Diabetes’s adjusted operating margin decreased by 3.5 percentage points over the last five years, but it rose by 9.9 percentage points on a two-year basis. Still, shareholders will want to see Tandem Diabetes become more profitable in the future.
Tandem Diabetes’s adjusted operating margin was negative 5.4% this quarter.
Earnings Per Share
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
Sadly for Tandem Diabetes, its EPS declined by 66.5% annually over the last five years while its revenue grew by 11.5%. This tells us the company became less profitable on a per-share basis as it expanded.
We can take a deeper look into Tandem Diabetes’s earnings to better understand the drivers of its performance. As we mentioned earlier, Tandem Diabetes’s adjusted operating margin expanded this quarter but declined by 3.5 percentage points over the last five years. Its share count also grew by 5.1%, meaning the company not only became less efficient with its operating expenses but also diluted its shareholders.
In Q2, Tandem Diabetes reported EPS of negative $0.31, up from negative $0.78 in the same quarter last year. This print beat analysts’ estimates by 2.7%. Over the next 12 months, Wall Street expects Tandem Diabetes to improve its earnings losses. Analysts forecast its full-year EPS will improve from negative $0.93 to negative $0.22.
Key Takeaways from Tandem Diabetes’s Q2 Results
It was encouraging to see Tandem Diabetes meet analysts’ EPS expectations this quarter. Zooming out, we think this was a decent quarter. The stock remained flat at $18.76 immediately after reporting.
Big picture, is Tandem Diabetes a buy here and now? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. .